3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Small Cell Lung Carcinoma
1
Sarcoma
1
Resectable Hepatocellular Carcinoma
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Interventions
Bevacizumab
23
Sorafenib
20
Doxorubicin
14
Gemcitabine
11
durvalumab
10
Oxaliplatin
10
Fluorouracil
10
Cisplatin
10
Capecitabine
9
Nivolumab
8
pembrolizumab
6
Sunitinib
6
tremelimumab
5
atezolizumab
5
Radiofrequency Ablation
5
Neoadjuvant Therapy
5
Leucovorin
5
lenvatinib
4
aldesleukin
4
Thalidomide
4
Radiotherapy
4
Radiosurgery
4
Everolimus
4
Erlotinib Hydrochloride
4
Drug Therapy
4
Carboplatin
4
toripalimab
3
regorafenib
3
camrelizumab
3
apatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liver Neoplasms
×
ADI PEG20
×
Clear all
NCT02006030
2018-09-04
TACE
Polaris Group
Phase 2
Completed
30 enrolled